Ovarian cancer often resembles an autoimmune disorder. These patients may be difficult to cross-match, and it has been observed that they have an antibody that interferes with cross-matching. Such an antibody, which may occur in patients who have not been transfused, reacts against normal tissue but does not recognize the ovarian cancer antigen. It can be suppressed after cortisone treatment. For 2 to 3 days following this therapy it is possible to cross-match the patient. In addition, the use of anticancer drug treatment gives the patient a sense of well-being long before there is any effect on tumor volume. These observations are suggestive but not conclusive that an autoimmune disorder results from the ovarian cancer.
KeywordsArthritis Lymphoma Leukemia Corticosteroid Glycol
Unable to display preview. Download preview PDF.
- Barber HRK: Immunobiology for the Clinician. John Wiley & Sons, New York, 1977.Google Scholar
- Burnet FN: The Clonal Selection Theory of Acquired Immunity. Cambridge University Press, Cambridge, 1959.Google Scholar
- Burnet FN: Cellular Immunology. Cambridge University Press, Cambridge, 1970.Google Scholar
- Fudenberg HH, Stites DP, Caldwell JR, Wells JV: Basic and Clinical Immunology. Lange Medical Publications, Los Altos, CA, 1976.Google Scholar
- Gershon RK: T cell control of antibody production In Cooper MD, Warner NL (eds): Contemporary Topics in Immunology. Vol. 3. Plenum, New York, 1974.Google Scholar
- Harris JE, Sirkovics JG: The Immunology of Malignant Disease. Mosby, St. Louis, 1970.Google Scholar
- Hemet R, McKern T (eds): Monoclonal Antibodies. Plenum Press, New York, 1980.Google Scholar
- Siegel MM, Good RA (eds): Tolerance, Autoimmunity and Aging. Charles C Thomas, Springfield, IL, 1972.Google Scholar
- Thomas L: Experimental mycoplasma infections as models of rheumatoid arthritis. Fed Proc 32: 143, 173.Google Scholar
- Yaltan DE, Roberts SB, Scharff MD: Hybridomas and monoclonal antibodies. Lab Management 19 (1): 19, 1981.Google Scholar